Not Signed In - Multiple Myeloma Patients Respond To Retreatment With VELCADE(R) (Bortezomib) For Injection
Tue, 12 Dec 2006 08:00 AM EST
... Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced findings from two retrospective analyses evaluating VELCADE(R)(bortezomib) for Injection as retreatment therapy in heavily pretreated relapsed multiple myeloma (MM) patients. [click link for full article] ...
Related Topics
- Myeloma, Multiple
- Multiple Myeloma
- Myeloma
- Bortezomib
- Thalidomide
- Multiple myeloma cancer
- Multiple Myeloma/Other Plasma Cell Neoplasms
- Multiple Myeloma/Plasma Cell Neoplasm
- Plasma Cell Neoplasm/Multiple Myeloma
- Multiple Chemical Sensitivity
- Some types of cervical cancer do not respond well to treatment.
- Twins, Triplets, Multiple Births
- Interferon Beta-1a Injection (Rebif
- Multiple System Atrophy
- Interferon Beta-1a Injection (Avonex
- Dicyclomine Injection
- Cortisone Injection
- Recessive multiple epiphyseal dysplasia
- Seizures (in about half of patients)
- Vaccinations For HIV/AIDs Patients
email this page
print this page
bookmark this page
feedback on this page
